MARKET

CBAY

CBAY

CymaBay
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.420
+0.010
+0.71%
After Hours: 1.360 -0.06 -4.23% 18:14 04/03 EDT
OPEN
1.410
PREV CLOSE
1.410
HIGH
1.460
LOW
1.380
VOLUME
1.12M
TURNOVER
--
52 WEEK HIGH
13.89
52 WEEK LOW
1.210
MARKET CAP
97.81M
P/E (TTM)
-0.9263
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 10 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average CBAY stock price target is 2.733 with a high estimate of 5.00 and a low estimate of 1.500.

EPS

CBAY News

More
  • Edited Transcript of CBAY earnings conference call or presentation 12-Mar-20 8:30pm GMT
  • Thomson Reuters StreetEvents · 3d ago
  • Generic Drugs Industry's Prospects Uncertain Amid Coronavirus
  • Zacks · 03/20 15:44
  • We're Keeping An Eye On CymaBay Therapeutics's (NASDAQ:CBAY) Cash Burn Rate
  • Simply Wall St. · 03/20 11:30
  • B. Riley FBR Maintains Neutral on CymaBay Therapeutics, Lowers Price Target to $1.5
  • Benzinga · 03/18 11:00

Industry

Biotechnology & Medical Research
-0.50%
Pharmaceuticals & Medical Research
-0.22%

Hot Stocks

Symbol
Price
%Change

About CBAY

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company's product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout. MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta (PPARd). The Company has completed over five Phase I clinical studies and a Phase II clinical study for MBX-8025. MBX-2982 is an oral, G-protein coupled receptor agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes (T2DM), with a dual mechanism, including direct effects and indirect effects mediated by gastrointestinal hormones known as incretins on glucose-dependent insulin secretion, as well as potentially beneficial effects on islet health. The Company has completed over four Phase I clinical studies and a Phase II clinical study for MBX-2982.
More

Webull offers kinds of CymaBay Therapeutics Inc stock information, including NASDAQ:CBAY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CBAY stock news, and many more online research tools to help you make informed decisions.